GW 4064

01/01/2023 - "Gratifyingly, the combination of PD-L1 antibody with GW4064 exhibited excellent anti-tumor effects in CT26 xenograft models and increased CD8+ T cells infiltration, with 33% tumor bearing mice cured. "
02/22/2016 - "In vivo xenograft studies, using MCF-7 cells alone or co-injected with CAFs, showed that GW4064 administration markedly reduced tumor growth. "
01/01/2023 - "Disappointingly, GW4064 could not suppress the growth of CRC tumors in vivo. "
01/01/2021 - "Importantly, FXR agonist (GW4064) can synergize with anti-PD-1 antibody (Ab) to inhibit HCC growth in tumor-bearing models. "
01/01/2021 - "To assess the effects of GW4064 on ESCC development in vivo, a xenograft tumor model was constructed. "

01/01/2017 - "Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice."
03/01/2017 - "This study investigated the effect of LQ, metformin [an activator of activated AMP-activated protein kinase (AMPK)] and GW4064 [a ligand of farnesoid X receptor (FXR)] on mitochondrial dysfunction and oxidative stress induced by serum deprivation as well as its molecular mechanism, as assessed by immunoblot and flow cytometer assays. "

11/07/2022 - "These findings suggest that FXR may be a new therapeutic target and that GW4064 may be helpful in the treatment of hilar cholangiocarcinoma."
11/07/2022 - "The study objective was to observe the treatment effect of the farnesoid X receptor (FXR) agonist GW4064 in a rat model of hilar cholangiocarcinoma to explore a new therapeutic target for gene therapy for hilar cholangiocarcinoma. "
11/07/2022 - "Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats."

01/13/2017 - "The key molecules, p62/SQSTM1, Nrf2 and SHP were upregulated in fatty liver tissue by GW4064 treatment. "
01/13/2017 - "In the hepatectomy model of db/db mice with fatty liver, pre-treatment by GW4064 significantly reduced post-PH liver injury (serum levels of LDH, AST & ALT and histological study) and improved steatosis. "

04/21/2006 - "Finally, treatment with GW4064 improved insulin resistance in genetically obese ob/ob mice in vivo. "
04/01/2021 - "We treated db/db mice with the FXR agonist GW4064 for 3 months and evaluated insulin resistance, lipid metabolism, renal functional changes, and structural changes in organs including those of the kidney, liver, pancreas, adipose tissue, aorta, and heart. "
05/01/2013 - "Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance."